Global Transplantation of Multipotent Hematopoietic Stem Cells Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Transplantation of Multipotent Hematopoietic Stem Cells Market Insights, Forecast to 2034
Over 50 years of studies in the field of blood-forming stem cells i.e. hematopoietic stem cells (HSC), researchers have developed significant understanding to use HSCs as a therapy. At present, no type of stem cell, adult, embryonic or fetal has attained such sufficient status. Hematopoietic stem cell transplantation (HSCT) is now routinely used for treating patients with malignant and non-malignant disorders of blood and the immune system. Currently, researchers have observed that through animal studies HSCs have the ability to form other cells such as blood vessels, muscles, and bone.
Market Analysis and InsightsGlobal Transplantation of Multipotent Hematopoietic Stem Cells Market
Global Transplantation of Multipotent Hematopoietic Stem Cells market is expected to reach to US$ 1483 million in 2023, with a positive growth of %, compared with US$ 1348 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Transplantation of Multipotent Hematopoietic Stem Cells industry is evaluated to reach US$ 2627.2 million in 2033. The CAGR will be 10.0% during 2023 to 2033.
The Transplantation of Hematopoietic Stem Cells market is primarily driven by its potential to provide curative treatments for various hematological disorders, including leukemia, lymphoma, and certain genetic diseases. Hematopoietic stem cell transplantation (HSCT) involves replacing damaged or malfunctioning bone marrow with healthy stem cells to restore normal blood cell production. The increasing prevalence of hematological diseases, coupled with advancements in transplantation techniques, contributes to market growth. Moreover, the demonstrated benefits of HSCT in achieving long-term remission, improving overall survival rates, and offering a potential cure for patients with limited treatment options further propel adoption. However, challenges include finding suitable donors, addressing potential graft-versus-host disease and other complications, and managing post-transplant care. Navigating patient-donor matching, ensuring graft compatibility, and providing comprehensive patient support are ongoing concerns. The market's success relies on continuous research in transplantation science, collaborations between medical institutions and stem cell banks, and comprehensive education on the benefits and potential challenges of hematopoietic stem cell transplantation while addressing the evolving challenges associated with donor availability and patient outcomes.
Report Covers
This report presents an overview of global Transplantation of Multipotent Hematopoietic Stem Cells market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Transplantation of Multipotent Hematopoietic Stem Cells market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
CBR Systems
China Cord Blood Corporation
ViaCord
Thermo Fisher Scientific
STEMCELL Technologies
Vcanbio
Merck Millipore
Lonza Group
CellGenix Technologie Transfer
ThermoGenesis
Segment by Type
Stem Cells Storage
Stem Cells Consumables
Leukemia
Lymphoproliferative Disorders
Solid Tumors
Non-Malignant Disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Transplantation of Multipotent Hematopoietic Stem Cells introduction, etc. Transplantation of Multipotent Hematopoietic Stem Cells Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Transplantation of Multipotent Hematopoietic Stem Cells
Chapter 13Methodology and Data Sources adopted by MRAResearch
Market Analysis and InsightsGlobal Transplantation of Multipotent Hematopoietic Stem Cells Market
Global Transplantation of Multipotent Hematopoietic Stem Cells market is expected to reach to US$ 1483 million in 2023, with a positive growth of %, compared with US$ 1348 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Transplantation of Multipotent Hematopoietic Stem Cells industry is evaluated to reach US$ 2627.2 million in 2033. The CAGR will be 10.0% during 2023 to 2033.
The Transplantation of Hematopoietic Stem Cells market is primarily driven by its potential to provide curative treatments for various hematological disorders, including leukemia, lymphoma, and certain genetic diseases. Hematopoietic stem cell transplantation (HSCT) involves replacing damaged or malfunctioning bone marrow with healthy stem cells to restore normal blood cell production. The increasing prevalence of hematological diseases, coupled with advancements in transplantation techniques, contributes to market growth. Moreover, the demonstrated benefits of HSCT in achieving long-term remission, improving overall survival rates, and offering a potential cure for patients with limited treatment options further propel adoption. However, challenges include finding suitable donors, addressing potential graft-versus-host disease and other complications, and managing post-transplant care. Navigating patient-donor matching, ensuring graft compatibility, and providing comprehensive patient support are ongoing concerns. The market's success relies on continuous research in transplantation science, collaborations between medical institutions and stem cell banks, and comprehensive education on the benefits and potential challenges of hematopoietic stem cell transplantation while addressing the evolving challenges associated with donor availability and patient outcomes.
Report Covers
This report presents an overview of global Transplantation of Multipotent Hematopoietic Stem Cells market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Transplantation of Multipotent Hematopoietic Stem Cells market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
CBR Systems
China Cord Blood Corporation
ViaCord
Thermo Fisher Scientific
STEMCELL Technologies
Vcanbio
Merck Millipore
Lonza Group
CellGenix Technologie Transfer
ThermoGenesis
Segment by Type
Stem Cells Storage
Stem Cells Consumables
Segment by Application
Leukemia
Lymphoproliferative Disorders
Solid Tumors
Non-Malignant Disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Transplantation of Multipotent Hematopoietic Stem Cells introduction, etc. Transplantation of Multipotent Hematopoietic Stem Cells Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Transplantation of Multipotent Hematopoietic Stem Cells
Chapter 13Methodology and Data Sources adopted by MRAResearch
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices